Koninklijke Philips (NYSE:PHG) Position Cut by Signaturefd LLC

Signaturefd LLC trimmed its holdings in Koninklijke Philips (NYSE:PHG) by 5.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 26,856 shares of the technology company’s stock after selling 1,545 shares during the quarter. Signaturefd LLC’s holdings in Koninklijke Philips were worth $680,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PHG. PNC Financial Services Group Inc. grew its holdings in Koninklijke Philips by 4.8% in the 3rd quarter. PNC Financial Services Group Inc. now owns 36,291 shares of the technology company’s stock worth $1,187,000 after buying an additional 1,676 shares in the last quarter. West Family Investments Inc. bought a new position in Koninklijke Philips during the 3rd quarter valued at $252,000. Charles Schwab Investment Management Inc. boosted its stake in Koninklijke Philips by 26.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 55,290 shares of the technology company’s stock valued at $1,809,000 after purchasing an additional 11,538 shares in the last quarter. Cerity Partners LLC boosted its stake in Koninklijke Philips by 16.8% during the 3rd quarter. Cerity Partners LLC now owns 60,112 shares of the technology company’s stock valued at $1,967,000 after purchasing an additional 8,625 shares in the last quarter. Finally, Pitcairn Co. bought a new position in Koninklijke Philips during the 3rd quarter valued at $256,000. 13.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

PHG has been the subject of a number of research reports. StockNews.com raised Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. BNP Paribas raised Koninklijke Philips from a “neutral” rating to an “outperform” rating in a research note on Tuesday, February 25th. Finally, UBS Group raised Koninklijke Philips from a “neutral” rating to a “buy” rating in a research note on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy”.

Koninklijke Philips Stock Performance

PHG opened at $26.79 on Thursday. The firm has a market cap of $25.18 billion, a PE ratio of -31.89, a P/E/G ratio of 0.82 and a beta of 0.78. The company has a quick ratio of 0.74, a current ratio of 1.23 and a debt-to-equity ratio of 0.59. The business has a fifty day simple moving average of $26.73 and a 200-day simple moving average of $27.78. Koninklijke Philips has a fifty-two week low of $19.10 and a fifty-two week high of $32.91.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings data on Wednesday, February 19th. The technology company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.01). The company had revenue of $5.38 billion for the quarter, compared to the consensus estimate of $5.10 billion. Koninklijke Philips had a positive return on equity of 10.85% and a negative net margin of 3.88%. As a group, equities analysts predict that Koninklijke Philips will post 1.63 EPS for the current fiscal year.

Koninklijke Philips Cuts Dividend

The firm also recently announced an annual dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 13th will be issued a $0.886 dividend. The ex-dividend date of this dividend is Tuesday, May 13th. This represents a dividend yield of 2.9%. Koninklijke Philips’s payout ratio is currently -89.29%.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.